{
    "2021-07-18": [
        [
            {
                "time": "2021-07-18",
                "original_text": "孙飘扬再出山背后：PD-1增长已至尾声，恒瑞医药将迎至暗时刻",
                "features": {
                    "keywords": [
                        "孙飘扬",
                        "PD-1",
                        "恒瑞医药",
                        "增长尾声",
                        "至暗时刻"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-07-18",
                "original_text": "恒瑞医药(600276.SH)：注射用甲苯磺酸瑞马唑仑、注射用HRS3797获批临床试验",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "甲苯磺酸瑞马唑仑",
                        "HRS3797",
                        "临床试验"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-07-18",
                "original_text": "医药行业周报：中报预告落地 个股表现持续分化",
                "features": {
                    "keywords": [
                        "医药行业",
                        "中报预告",
                        "个股分化"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-07-18",
                "original_text": "恒瑞医药：子公司收到两项药物临床试验批准通知书",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "子公司",
                        "临床试验",
                        "批准通知书"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-07-18",
                "original_text": "恒瑞医药：子公司药品获批开展临床试验",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "子公司",
                        "药品",
                        "临床试验"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-07-18",
                "original_text": "恒瑞医药：子公司收到注射用甲苯磺酸瑞马唑仑、注射用HRS3797的药物临床试验批准通知书",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "子公司",
                        "甲苯磺酸瑞马唑仑",
                        "HRS3797",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}